 Disease-Free Survival
"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 | | 1996 | 0 | 6 | 6 | | 1997 | 0 | 7 | 7 | | 1998 | 0 | 10 | 10 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 9 | 9 | | 2002 | 0 | 10 | 10 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 8 | 8 | | 2005 | 0 | 10 | 10 | | 2006 | 0 | 7 | 7 | | 2007 | 0 | 15 | 15 | | 2008 | 0 | 15 | 15 | | 2009 | 0 | 12 | 12 | | 2010 | 0 | 29 | 29 | | 2011 | 0 | 19 | 19 | | 2012 | 0 | 29 | 29 | | 2013 | 0 | 40 | 40 | | 2014 | 0 | 35 | 35 | | 2015 | 0 | 42 | 42 | | 2016 | 0 | 37 | 37 | | 2017 | 0 | 55 | 55 | | 2018 | 0 | 28 | 28 | | 2019 | 0 | 35 | 35 | | 2020 | 0 | 22 | 22 | | 2021 | 0 | 12 | 12 | | 2022 | 0 | 9 | 9 | | 2023 | 0 | 8 | 8 | | 2024 | 0 | 6 | 6 | | 2025 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Akabane M, Kawashima J, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. International validation of a natural-killer-cell-based model to predict recurrence-free survival in hepatocellular carcinoma. HPB (Oxford). 2025 Oct; 27(10):1259-1269.
-
Akabane M, Kawashima J, Woldesenbet S, Lee GR, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Distinct patterns of late recurrence in long-term hepatocellular carcinoma survivors. J Gastrointest Surg. 2025 Sep; 29(9):102135.
-
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Oliveira S, Balaia J, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Unraveling the obesity paradox in hepatocellular carcinoma: relative role of elevated body mass index on detrimental effects of postoperative complications. HPB (Oxford). 2025 Aug; 27(8):1103-1112.
-
Akiki A, Jacobsson H, Nouairia G, Cornillet M, Björkström NK, Sparrelid E, Taflin H, Jansson H. External validation of plasma CSF1 as a preoperative prognostic marker in patients with resectable intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2025 Aug; 51(8):110123.
-
Guenther JM, Ward A, Martin BJ, Cripe M, Beard T, Wisco O, Sharma R, Leong SP, Essner R, Clark JI, Hamner J, Sickle-Santanello B, Yamamoto M. A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP. Cancer Med. 2025 Apr; 14(7):e70839.
-
Tran K, Oh D, Tsang R, Suh CO, Yoon HI, Byun HK, Taguchi S, Gunther JR, Dabaja B, Pinnix CC, Plastaras J, Wright C, Imber BS, Yahalom J, Elsayad K, Eich HT, Ng AK, Rabinovitch R, Binkley MS, Hoppe RT, Brady JL, Mikhaeel NG, Wang X, Qi S, Levis M, Ricardi U, Harris M, Illidge TM, MacManus M, Bressel M, Wirth A. An International Lymphoma Radiation Oncology Group Study of Radiation Therapy for Bilateral Indolent Orbital Adnexal Lymphomas. Int J Radiat Oncol Biol Phys. 2025 Aug 01; 122(5):1207-1216.
-
Carbonara U, Ditonno F, Beksac AT, Derweesh I, Cerrato C, Celia A, Costa G, Bianchi L, Elbich J, Wilson B, Hampton LJ, Pandolfo SD, Basile G, Kim FJ, Schiavina R, Capitanio U, Kaouk J, Autorino R. Percutaneous Cryotherapy and Radiofrequency Ablation of Renal Masses: Multicenter Comparative Analysis with Minimum 3-Year Follow-up. Int Braz J Urol. 2025 Mar-Apr; 51(2).
-
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 Feb; 193:119-129.
-
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|